Literature DB >> 20486995

YKL-40 concentrations are not elevated in gestational diabetes.

Georg Schaller1, Johanna Maria Brix, Gudrun Placher-Sorko, Florian Höllerl, Gerit-Holger Schernthaner, Guntram Schernthaner.   

Abstract

BACKGROUND: Gestational diabetes (GDM) is an increasing and common complication of pregnancy. The involvement of inflammatory mechanisms in GDM remains unclear. YKL-40 is a novel inflammatory marker that has been recently found to be associated with type 2 diabetes. This is the first study to investigate YKL-40 in GDM.
MATERIAL AND METHODS: A total of 58 subjects were included, 28 patients with GDM (BMI 33.2 +/- 6.1 kg m(-(2)), 33 +/- 6 years) and 30 healthy pregnant controls (BMI 28.4 +/- 5.2 kg m(-(2)), 33 +/- 4 years; mean +/- SD). Standard risk factors for GDM (weight and BMI prior to pregnancy, family history, former GDM, high birthweight offspring) were evaluated. A 2-h 75-g oral glucose tolerance test (oGTT) and measurement of YKL-40 were conducted in gestational week 28 +/- 4, as well as 8 weeks after delivery.
RESULTS: YKL-40 was not different between GDM and controls, neither during (65.8 +/- 44.4 vs. 60.3 +/- 30.1 ng mL(-1)), nor after pregnancy (63.4 +/- 30.5 vs. 66.9 +/- 32.7 ng mL(-1)). YKL-40 was correlated with insulin, HOMA and BMI. GDM had higher fasting insulin (14.1 +/- 7.4 vs. 8.3 +/- 4.3 muU mL(-1)) and glucose (88 +/- 13 - 200 +/- 31 - 160 +/- 33 vs. 76 +/- 10 - 146 +/- 37 - 112 +/- 28 mg dL(-1) for fasting, 1- and 2-h-concentrations in the oGTT, respectively), higher HbA1c (5.3 +/- 0.4 vs. 5.0 +/- 0.5%;), HOMA (3.1 +/- 1.7 vs. 1.6 +/- 0.9), and BMI (33.2 +/- 6.1 vs. 28.5 +/- 5.2 kg m(-2)) (means +/- SD, all P < 0.01).
CONCLUSIONS: No difference in YKL-40 between GDM and controls suggests similar inflammatory status at the time of measurements. The short duration of metabolic changes during GDM might explain this finding, which is in contrast to results in type 2 diabetes.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20486995     DOI: 10.1111/j.1365-2362.2010.02274.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  4 in total

1.  Alteration in Uterine Protease-Activated Receptor 2 Expression in Preterm Birth Induced Experimentally in Brp-39 Null Mutant Mice.

Authors:  Ja Yun Jang; Yi Seul Kim; Yu Mi Han; So Young Kang; Jung-Sun Kim
Journal:  Reprod Sci       Date:  2018-07-11       Impact factor: 3.060

2.  Estimation of YKL-40 Levels in Serum and Gingival Crevicular Fluid in Chronic Periodontitis and Type 2 Diabetes Patients among South Indian Population: A Clinical Study.

Authors:  Prathush Ajit Kumar; Krishna Kripal; Kavita Chandrasekaran; Sushma Reddy Bhavanam
Journal:  Contemp Clin Dent       Date:  2019 Apr-Jun

3.  Increased levels of YKL-40 in patients with diabetes mellitus: a systematic review and meta-analysis.

Authors:  Wanwan Luo; Lingmin Zhang; Lingling Sheng; Zhencheng Zhang; Zaixing Yang
Journal:  Diabetol Metab Syndr       Date:  2021-01-15       Impact factor: 3.320

4.  Differential proinflammatory and oxidative stress response and vulnerability to metabolic syndrome in habitual high-fat young male consumers putatively predisposed by their genetic background.

Authors:  Pedro González-Muniesa; María Pilar Marrades; José Alfredo Martínez; María Jesús Moreno-Aliaga
Journal:  Int J Mol Sci       Date:  2013-08-22       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.